
Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19
For investors looking to cash in on a burgeoning ear therapy space, the latest biotech angling for a public debut could be music to their ears.
Fresh off a $105 million raise in March, ear gene therapy company Akouos is looking for another $100 million for a chance to dance on the Nasdaq well before its lead product enters the clinic.
Hearing aids and cochlear implants do address ear damage caused by genetics, noise, aging, or drugs, but nothing quite cures or indeed targets the biological underpinnings of hearing loss — this is the gap Akouos and a handful of others in the space want to bridge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.